Table 4 Treatment efficacy
N 113 | (%) | |
|---|---|---|
Total number of chemotherapy cycles | 611 | |
Median number of chemotherapy cycles (range) | 4 | (1–27) |
Dose reduction (patients) | 32 | (28.3) |
Dose reduction (cycles) | 101 | (16.5) |
Cycle delay (patients) | 23 | (3.7) |
Cycle delay (no) | 33 | (5.4) |
Tumor response | ||
Complete response | – | |
Partial response | 27 | (24.0) |
95 % CI | (16.0–31.8) | |
Stable disease | 29 | (25.7) |
Progressive disease | 51 | (45.1) |
Not evaluable | 7 | (6.2) |
Disease control rate | 56 | (49.5) |
Clinical benefit | 40 | (35.4) |
95 % CI | 26.6–44.2 | |
Median PFS (months, range) | 3.3 (0.6–26.7) | |
95 % CI | 2.4–4.2 | |
Median OS (months, range) | 11.6 (0.6–33.3) | |
95 % CI | 8.7–14.5 |